Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Azar: International Regulatory Harmonization Will Create More Stable Generic Markets

Executive Summary

HHS secretary tells AAM that "fundamental" changes require legislation, but "FDA and our peers are exploring new potential areas for alignment."

You may also be interested in...



HHS Rebate Plan A Leap Of Faith? Lower Costs Hinge On Drug Firm, Plan Response

HHS seeks input on how stakeholders might adjust to a system without rebates and requests comments on three actuarial reports that attempt to project the financial impact of the change.

Biosimilar Bridging Study Waivers: Public Health Prerogative Or Trade Secret ‘Taking’?

US FDA and PhRMA may be headed for showdown over use of foreign reference product bridging studies; PhRMA says that relying on sponsor’s non-public information to waive bridging studies  would violate firm’s commercial confidential information, while FDA Commissioner Gottlieb sees ‘public health prerogative’ in considering whether data-sharing agreements with foreign regulators could help eliminate need for unnecessary studies.

At US Generic Association Annual Meeting, Worries About Sustainability

ANDA sponsors fret price erosion – and potential changes to 180-day exclusivity.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS124712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel